| Title | Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. | | Author(s) | Glas M, Hundsberger T, Stuplich M, Wiewrodt D, Kurzwelly D, Nguyen-Huu B, Rasch K, Herrlinger U | | Institution | Department of Neurology, Clinical Neurooncology Unit, University of Bonn, Bonn, Germany. | | Source | Oncology 2009; 76(3):184-9. | | MeSH | Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Brain Neoplasms
Female
Glioblastoma
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
Nimustine
Retrospective Studies
Teniposide
| | Abstract | BACKGROUND: In a previous trial (NOA-01), the combination of nimustine and teniposide showed efficacy in previously untreated glioblastoma (GBM). After establishing temozolomide as standard first-line therapy in GBM patients, the nimustine (ACNU)/teniposide (VM-26) combination has been employed as salvage chemotherapy for recurrent GBM. However, data on the toxicity and efficacy of this regimen in recurrent GBM are lacking.
PATIENTS AND METHODS: In two neurooncological centers, all patients with recurrent GBM treated with nimustine (90 mg/m(2), day 1/42) and teniposide (45-70 mg/m(2), days 1-3/42) were analyzed retrospectively for progression-free survival (PFS), overall survival (OS) and toxicity.
RESULTS: Thirty-five patients (median age 51 years, range 25-71 years) were identified. Six months after chemotherapy initiation, PFS was 29% and the median OS 6 months; 23% of patients were alive > or = 1 year after initiation of nimustine-teniposide chemotherapy. Grade 4 hematotoxicity was observed in 12 of 35 patients (34%) and in 14 of 83 evaluable chemotherapy courses (17%).
CONCLUSIONS: The benefit of the nimustine-teniposide combination is moderate in patients with recurrent GBM. The data support the efficacy of the nimustine-teniposide chemotherapy, but the rate of high-grade hematotoxicity is increased. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19218824 |
|
